Eastgroup Properties (EGP) Misses Q4 EPS by 3c
Get Alerts EGP Hot Sheet
Price: $203.22 +1.63%
Revenue Growth %: +9.1%
Financial Fact:
Income from real estate operations: 63.18M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +9.1%
Financial Fact:
Income from real estate operations: 63.18M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Eastgroup Properties (NYSE: EGP) reported Q4 EPS of $0.51, $0.03 worse than the analyst estimate of $0.54.
- Net Income Attributable to Common Stockholders of $0.51 Per Share (Same as the Fourth Quarter of 2017)
- Funds from Operations of $1.18 Per Share Compared to $1.14 Per Share for the Fourth Quarter of 2017, an Increase of 3.5%
- Same Property Net Operating Income (PNOI) for the Annual Same Property Pool (Excluding Income From Lease Terminations) for Fourth Quarter 2018 Increased 2.5% on a Straight-Line Basis and 3.7% on a Cash Basis Compared to Fourth Quarter 2017
- 97.3% Leased, 96.8% Occupied as of December 31, 2018; Average Occupancy of 96.5% for the Quarter
- Rental Rates on New and Renewal Leases Increased an Average of 16.6%
- Acquired a 45,000 Square Foot Operating Property in Austin for $4 Million
- Acquired 53 Acres of Development Land in Phoenix and San Antonio for $10 Million
- Started Construction of a Development Project Comprised of Two Buildings Containing 139,000 Square Feet in Dallas with Projected Total Costs of $15 Million
- Transferred Four 100% Leased Development Projects (381,000 Square Feet) to the Real Estate Portfolio
- Declared 156th Consecutive Quarterly Cash Dividend: $0.72 Per Share
- Issued 460,589 Shares of Common Stock at an Average Price of $98.77 During the Quarter with Gross Proceeds of $45.5 Million
For earnings history and earnings-related data on Eastgroup Properties (EGP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Sun Communities names Ileana McAlary as general counsel and EVP
- Pfizer lung cancer drug misses survival goal in Phase 3 trial
Create E-mail Alert Related Categories
EarningsRelated Entities
Dividend, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share